Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

We describe the case of an acromegalic subject, who was the first patient e ver treated with the GH receptor antagonist pegvisomant. Furthermore, in th is particular patient, progression in tumor size was encountered during tre atment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalizat ion of serum insulin-like growth factor I concentrations, and improvement o f visual field defects.